BI-2536 is a polo-like kinase 1 (PLK-1) inhibitor used for the treatments of leukemia, carcinoma, pancreatic neoplasms, and non-small-cell lung cancer. This evidence concerns the gene PLK1 and pancreatic neoplasm.